Cannabidiol as a pharmacotherapy tool for attenuating methamphetamine effects.

Am J Drug Alcohol Abuse

Instituto de Biología Celular y Neurociencia "Prof. Eduardo De Robertis" (IBCN), CONICET- Universidad de Buenos Aires, Buenos Aires, Argentina.

Published: September 2022

Download full-text PDF

Source
http://dx.doi.org/10.1080/00952990.2022.2098758DOI Listing

Publication Analysis

Top Keywords

cannabidiol pharmacotherapy
4
pharmacotherapy tool
4
tool attenuating
4
attenuating methamphetamine
4
methamphetamine effects
4
cannabidiol
1
tool
1
attenuating
1
methamphetamine
1
effects
1

Similar Publications

The present study aims to develop and characterize cannabidiol (CBD) solid dispersions using Vacuum Compression Molding (VCM) to enhance the drug solubility and release profile. Solid dispersions of CBD and polymers were processed using VCM at 130 °C for 4 min after a prior physical mixing. Five percent w/w of CBD was used with 5% w/w of poloxamer 188 and 90% w/w of polymeric carrier (Polyethylene Oxide, PEO-N80 or Hydroxypropyl cellulose, HPCEF).

View Article and Find Full Text PDF

White-Sutton syndrome (WSS), associated with gene mutations, is a rare genetic disorder characterized by a spectrum of phenotypic features, including intellectual disabilities, developmental delays, and epilepsy. A case report described a female patient diagnosed with WSS who experienced seizures resistant to conventional antiseizure medications. Despite various therapeutic attempts, including valproate, topiramate, levetiracetam, clobazam, rufinamide, and vigabatrin, the patient's seizures persisted.

View Article and Find Full Text PDF

Background: Lennox-Gastaut syndrome (LGS) is a severe encephalopathic disease that leads to a decrease in the quality of life, physical injury, psychosocial impairment, and a significant increase in treatment costs. Cannabidiol (CBD) is approved for the adjunctive treatment of tonic-colonic seizures in LGS. This study aimed to determine the cost-effectiveness of CBD compared to the usual treatment in patients with LGS syndrome.

View Article and Find Full Text PDF

Introduction: Many chemotherapy agents used to treat advanced cancer are inherently mucotoxic, causing breakdown of the gastrointestinal mucosa (gastrointestinal mucositis (GI-M)) and lead to a constellation of secondary complications including diarrhoea, malnutrition, anorexia, pain, fatigue and sleep disturbances. These symptoms are usually managed individually, leading to polypharmacy and its associated risks. The endocannabinoid system regulates numerous biological and behavioural processes associated with chemotherapy side effects, suggesting its modulation could control these symptoms.

View Article and Find Full Text PDF

Characterizing Cannabidiol Use in a Breast Cancer Population.

Clin Breast Cancer

February 2025

University of Michigan, Department of Internal Medicine, Ann Arbor, MI. Electronic address:

Introduction: Cannabidiol (CBD) is a phytocannabinoid found in the plant Cannabis sativa and is thought to have broad potential therapeutic value. Little is reported on CBD use in patients with breast cancer (BC). This survey study aimed to characterize CBD use patterns and reported benefits among patients with BC, while also identifying barriers and limitations to its use.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!